Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study.

Saved in:
Bibliographic Details
Title: Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study.
Authors: Podder V; Mount Sinai Medical Center, Miami Beach, FL, USA., Sarfraz Z; Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA., Ranjan T; Dartmouth Hitchcock Medical Center and Clinics, Lebanon, NH, USA., McCracken A; Guardian Research Network, Spartanburg, SC, USA., Hurmiz C; Guardian Research Network, Spartanburg, SC, USA., Hodgson L; Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA., Maharaj A; Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA., Mahtani R; Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA., Ahluwalia MS; Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA. manmeeta@baptisthealth.net.; Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA. manmeeta@baptisthealth.net.
Source: Scientific reports [Sci Rep] 2026 May 27. Date of Electronic Publication: 2026 May 27.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2045-2322
DOI:10.1038/s41598-026-50871-x